Associated Papers
Glucosylceramide Associated with Gaucher Disease Forms Amyloid-like Twisted Ribbon Fibrils That Induce α-Synuclein Aggregation.
Paul A et al.
Acs Nano, 2021
How we manage Gaucher Disease in the era of choices.
Revel-Vilk S et al.
British Journal of Haematology, 2018
Chitinase-3-like Protein 1: A Progranulin Downstream Molecule and Potential Biomarker for Gaucher Disease.
Jian J et al.
Ebiomedicine, 2018
Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease.
Zimran A et al.
Blood Cells, Molecules & Diseases, 2013
Pharmacological chaperone therapy for Gaucher disease: a patent review.
Benito JM et al.
Expert Opinion on Therapeutic Patents, 2011
Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells.
Rigat B et al.
Molecular Genetics and Metabolism, 2009
Neuropathology provides clues to the pathophysiology of Gaucher disease.
Wong K et al.
Molecular Genetics and Metabolism, 2004
Select a paper to view details